Evidence map›Paper›PMID 31598157›Full record

ArticleJournal of Cancer2019

Genetic variations in MAGE-A11 predict the risk and survival of renal cell cancer.

Shifeng Su, Qi Gu, Aiming Xu, Sipeng Shen, Shouyong Liu, Chao Zhang, Chengkui Miao, Chao Qin, Bianjiang Liu, Zengjun Wang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Diagnostics (Basel, Switzerland) · 2022
    Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Shifeng SuDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
Qi GuDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
Aiming XuDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
Sipeng ShenDepartment of Biostatistics, School of Public Health, Nanjing Medical University, Nanjing, 211166, Jiangsu, China.
Shouyong LiuDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
Chao ZhangDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
Chengkui MiaoDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
Chao QinDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
Bianjiang LiuDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
Zengjun WangDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
Nanjing Medical University · CNJiangsu Province Hospital · CNHarvard University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Melanoma antigen-A11 (

Indexed as

MAGE-A11renal carcinomasingle-nucleotide polymorphismsurvival

Identifiers

PMID31598157
PMCPMC6775520
OpenAlexW2972657198

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.